NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company is headquartered in South San Francisco, California and currently employs 239 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying grievous diseases with critical unmet or underserved patient need. The Company’s portfolio of product candidates includes NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin, NGM936 and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). The firm's NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.

Industry: Pharmaceutical Preparations Peers: Aclaris Therapeutics Inc Amphastar Pharmaceuticals, Inc. Relmada Therapeutics Inc CinCor Pharma, Inc. Johnson & Johnson Pliant Therapeutics Inc